BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001). ClinicalTrials.gov record last updated 2026-10-05: recruiting. Enrollment is planned at 355 participants. Primary completion is estimated at 2030-03. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: AVZO-103, Combination Agent. Registered primary measures: Occurrence of Dose Limiting Toxicities (DLTs) during the first cycle (Phase 1); Determine the maximum tolerated dose (MTD) and/or preliminary recommended Phase 2 dose (RP2D) (Phase 1); Number of Participants with Treatment Emergent Adverse Events (TEAEs) and lab abnormalities (Phase 1).